Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
SKiN Centre for Dermatology, Department of Dermatology, Queen's University, & Probity Medical Research, Peterborough, ON, Canada.
Immunotherapy. 2023 Aug;15(12):963-973. doi: 10.2217/imt-2023-0061. Epub 2023 May 7.
WHAT IS THIS SUMMARY ABOUT?: This is a summary of a paper published in a medical journal that describes the results of a study called POETYK PSO-1, which looked at a new treatment called deucravacitinib for plaque psoriasis. Plaque psoriasis appears on the body as round or oval raised patches (called plaques) typically covered by scales. This can cause the skin to itch, crack or bleed, and the associated itching and pain can make it difficult to perform basic everyday tasks. Living with psoriasis can cause emotional distress. Treatments are available, but some do not always reduce the symptoms of psoriasis, some may need to be injected or taken multiple times a day, and some may have side effects. Researchers are looking for new treatments that are more effective, convenient to take, and have acceptable safety and tolerability.
WHAT HAPPENED IN THE STUDY?: Deucravacitinib is a once-daily pill taken by mouth (orally) that was studied as a treatment for moderate to severe plaque psoriasis in adults in two large studies conducted globally, PSO-1 and PSO-2. The POETYK PSO-1 study compared deucravacitinib with placebo (an inactive pill designed to have no effect) and an approved psoriasis treatment called apremilast, which is a pill taken twice a day. These were tested in adults with moderate to severe plaque psoriasis, which involved 10% or more of their body (equal to 10 or more handprints). The aim of the study was to compare the ability of deucravacitinib with placebo or apremilast to improve psoriasis for the people in the study, and to compare side effects that people had.
WHAT DO THE RESULTS OF THE POETYK PSO-1 STUDY SHOW?: After 4 months of treatment, more people taking deucravacitinib had improvements in psoriasis plaques and skin appearance than those taking placebo or apremilast. The study also showed that people continued to see these improvements after taking deucravacitinib for up to 1 year. Side effects are events that happened during the study treatment phase that may or may not be caused by that treatment. Side effects for people taking deucravacitinib were generally mild and occurred in similar numbers overall to those in people taking placebo. The most common side effects in people taking deucravacitinib were inflammation or infection of the nasal (nose) passages and throat. NCT03624127 (POETYK PSO-1 study) (ClinicalTrials.gov).
这是一篇发表在医学期刊上的论文摘要，描述了一项名为 POETYK PSO-1 的研究结果，该研究针对一种名为 deucravacitinib 的新型斑块型银屑病治疗方法。斑块型银屑病表现为圆形或椭圆形凸起斑块（称为斑块），通常覆盖有鳞屑。这会导致皮肤瘙痒、破裂或出血，相关的瘙痒和疼痛会使基本日常活动变得困难。患有银屑病会导致情绪困扰。有可用的治疗方法，但有些方法并不总能减轻银屑病的症状，有些可能需要每天注射或服用多次，有些可能有副作用。研究人员正在寻找更有效、更方便服用且安全性和耐受性可接受的新治疗方法。
deucravacitinib 是一种每天口服一次的药丸，在两项全球开展的大型研究（PSO-1 和 PSO-2）中被研究作为成人中重度斑块型银屑病的治疗方法。POETYK PSO-1 研究比较了 deucravacitinib 与安慰剂（一种设计无效果的无效药丸）和一种已批准的银屑病治疗药物 apremilast（每天服用两次的药丸）。这些药物在中重度斑块型银屑病患者中进行了测试，这些患者的身体有 10%或更多（等于 10 个或更多手印）受累。该研究的目的是比较 deucravacitinib 与安慰剂或 apremilast 改善研究人群中银屑病的能力，并比较人们的不良反应。
POETYK PSO-1 研究结果显示，在治疗 4 个月后，接受 deucravacitinib 治疗的患者中，斑块型银屑病和皮肤外观改善的患者比例高于接受安慰剂或 apremilast 治疗的患者。该研究还表明，接受 deucravacitinib 治疗长达 1 年的患者仍能看到这些改善。不良反应是指在研究治疗期间发生的事件，可能与该治疗有关，也可能无关。接受 deucravacitinib 治疗的患者的不良反应通常为轻度，总体上与接受安慰剂治疗的患者的不良反应数量相似。接受 deucravacitinib 治疗的患者最常见的不良反应是鼻（鼻）道和喉咙的炎症或感染。NCT03624127（POETYK PSO-1 研究）（ClinicalTrials.gov）。
